Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.93 |
| ▸ | CTSB | P07858 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.44 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.44 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095733 | 0.96 | AR (1.00) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL3187856 | 0.79 | AR (0.62) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL6094071 | 0.78 | AR (1.00) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL6095739 | 0.78 | AR (1.00) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL7237528 | 0.78 | AR (1.00) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL6096119 | 0.78 | AR (1.00) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL7227693 | 0.78 | AR (1.00) | ARCTSBALDH1A1KDM4ETDP1 | |
| SCHEMBL7228589 | 0.78 | AR (1.00) | ARCTSBALDH1A1KDM4ETDP1 | |
| SCHEMBL3603749 | 0.75 | CTSB (1.00) | ARCTSBMAPTTNNI3TNNT2 | |
| SCHEMBL12543451 | 0.74 | AR (0.55) | ARMAPTSMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670386-B2 | For therapy of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | AR 1/4885CTSB 4450/4885MAPT 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.